BAXTER INTERNATIONAL INC's gross profit margin for the second quarter of its fiscal year 2015 has decreased when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its industry.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||3893.0||4051.0|
|Net Income ($mil)||332.0||520.0|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||0.0||1866.0|
|Total Assets ($mil)||0.0||25629.0|
|Total Debt ($mil)||0.0||8839.0|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||49.47||54.78|
|Return on Assets||0.0||7.59|
|Return on Equity||0.0||21.5|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||543.85||541.67|
|Div / share||0.52||0.52|
|Book value / share||0.0||15.99|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||7684138.0||3342088.0|
BUY. The current P/E ratio indicates a significant discount compared to an average of 36.23 for the Health Care Equipment & Supplies industry and a discount compared to the S&P 500 average of 21.25. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. After reviewing these and other key valuation criteria, BAXTER INTERNATIONAL INC proves to trade at a discount to investment alternatives within the industry.
|BAX 12.70||Peers 36.23||BAX NA||Peers 28.32|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
BAX is trading at a significant discount to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|BAX 28.18||Peers 25.39||BAX NM||Peers 0.98|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
BAX is trading at a premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
BAX's negative PEG ratio makes this valuation measure meaningless.
|BAX NA||Peers 15.81||BAX -6.81||Peers 2.31|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
Ratio not available.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BAX is expected to significantly trail its peers on the basis of its earnings growth rate.
|BAX 1.33||Peers 6.02||BAX 2.47||Peers 10.78|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BAX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BAX significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV